Form 4 for ACAD ACADIA PHARMACEUTICALS INC
Accepted 2025-11-19 00:00:00 ET · period of report 2025-11-17 · accession 0001899977-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-19 | 2025-11-17 | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | — | +19.8K | 63.6K | +45% | — |
| D | 2025-11-19 | 2025-11-18 | ACAD | Schneyer Mark C. | EVP, CFO | S - Sale+OE | $23.69 | -10.3K | 53.3K | -16% | -$243.1K |
| DM | 2025-11-19 | 2025-11-17 | ACAD | Schneyer Mark C. | EVP, CFO | M - OptEx | $0.00 | -19.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-17 | M | A | 9,913 | — | 53,687 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F2) Includes 327 shares of the Issuer's common stock acquired by the reporting person on November 14, 2025 pursuant to an employee stock purchase plan. |
| 2 | Common | Common Stock | 2025-11-17 | M | A | 9,913 | — | 63,600 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| 3 | Common | Common Stock | 2025-11-18 | S | D | 10,262 | $23.69 | 53,338 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.69 to $23.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
| 4 | Derivative | Restricted Stock Units | 2025-11-17 | M | D | 9,913 | $0.00 | 0 | D | — · — to — | 9,913 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F5) The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. |
| 5 | Derivative | Restricted Stock Units | 2025-11-17 | M | D | 9,913 | $0.00 | 0 | D | — · — to — | 9,913 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F6) The restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. In addition, these restricted stock units may vest earlier upon the Issuer's common stock achieving a specified price per share over a specified trading period. |